Document is current
Any future updates will be listed below
-
Authors
Zhang, Kailun David
Jost, Edgar
Panse, Jens
Herwartz, Reinhild
Lindemann-Docter, Katharina
Jonigk, Danny
Kricheldorf, Kim
Köchel, Anja
Sauerbrunn, Nicolas
Brümmendorf, Tim H.
Koschmieder, Steffen
Isfort, Susanne https://orcid.org/0000-0002-2855-561X
-
Funding
Funding for this research was provided by:
Universitätsklinikum RWTH Aachen
- License Information
-
More Information
Article History
Received: 17 October 2023
Accepted: 31 January 2024
First Online: 10 February 2024
Declarations
:
: The study has been approved by local Ethics Committee (Internal file number EK 309/22).
: Not applicable.
: KDZ, EJ, JP, RH, KL-D, DJ, KK, AK, NS and SK report no competing interests to declare that are relevant to the content of this article. THB served as consultant/speaker for Gilead, Janssen, Merck, Novartis, Pfizer, and received research support from Novartis and Pfizer. SI reports advisory board honoraria from GSK, Pfizer, Incyte, and Novartis, honoraria from Novartis, BMS, Pfizer, Incyte, AOP Orphan; and other financial support (e.g. travel support) from Alexion, Novartis, Pfizer, Mundipharma, Roche, Hexal and AOP Orphan.
